Sign In or Register
Highlights

Prolor Biotech Downgraded by Summer Street (PBTH)

 Source: ABMN Staff   |   Publish date: Mon, 12 Nov 11:58   |    >> Read article in News website

Prolor Biotech (NASDAQ: PBTH) was downgraded by research analysts at Summer Street from a “buy” rating to a “sell” rating in a report released on Monday.

Prolor Biotech traded down 3.16% on Monday, hitting $4.60. Prolor Biotech has a 52-week low of $3.11 and a 52-week high of $6.69. The company’s market cap is $291.7 million.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 29th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 22nd. They set a “buy” rating and a $8.00 price target on the stock.

Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins.

Share this

  Be the first to like this.
 


 

1432  1145  213 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 EBAY 55.89+2.49 
 INTC 35.15+0.65 
 JRJC 9.74+0.57 
 AAPL 100.58+0.01 
 SIRI 3.58+0.01 
 MSFT 45.22+0.27 
 CSCO 24.89+0.18 
 FB 74.57-0.24 
 ZNGA 3.06-0.06 
 QQQ 98.90+0.20 
Partners & Brokers